Partner Mary K. Braza was quoted in a San Francisco Business Times article, “Esports Joins the Big Leagues,” about how and why professional sports teams like the Golden State Warriors are investing in esports.
“A lot of it depends on the type of owner you have in the traditional sports,” said Braza, who co-chairs Foley’s sports industry team. “The Warriors owners are more interested in new technologies, they’re younger than a lot of owners and they’re more connected to the tech community.”
The article also noted the findings of Foley and The Esports Observer’s new esports survey including concerns about match fixing, net neutrality and illegal gambling.
“A lot of it depends on the type of owner you have in the traditional sports,” said Braza, who co-chairs Foley’s sports industry team. “The Warriors owners are more interested in new technologies, they’re younger than a lot of owners and they’re more connected to the tech community.”
The article also noted the findings of Foley and The Esports Observer’s new esports survey including concerns about match fixing, net neutrality and illegal gambling.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”